Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D. - Insights
Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal...
NELL-1 [Test in Focus] - Insights
Sanjeev Sethi, M.D., Ph.D., discusses how Mayo Clinic Laboratories’ new immunohistochemistry test for the detection of NELL-1 antigen, a biomarker for membranous nephropathy found in 10% to 15% of patients, provides diagnostic certainty and...
RNA test identifies large B-cell lymphoma subtypes: Lisa Rimsza, M.D. - Insights
Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately determine subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy.
Angela Pickart, M.S., CGC, and Emily Lauer, M.S., CGC, explain how Mayo Clinic Laboratories' multigene panel helps identify the cause of hereditary ataxia. Precise diagnosis of this complex movement disorder helps guide patient treatment...
Autoimmune Axonal Evaluation - Insights
Div Dubey, M.B.B.S., explains Mayo Clinic Laboratories' phenotypic testing approach for autoimmune axonal neuropathy. The comprehensive, serologic panel detects for antibodies with clinical relevance to the disease to provide clarity on...
Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC, explain how Mayo Clinic Laboratories' gene panel establishes a diagnosis of Lynch syndrome, which heightens the risk for several cancers. Test results can guide targeted cancer surveillance for...
TPNUQ genotyping assay - Insights
Ann Moyer, M.D., Ph.D., discusses TPNUQ, Mayo Clinic Laboratories' genotyping test for identifying patients at risk for thiopurine toxicity. Used prior to therapy initiation, our assay evaluates for nuances in both TPMT and NUDT15, which...
New gene panel enhances brain tumor profiles - Insights
Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.
Nonradioactive assay helps diagnose heparin reaction - Insights
Rajiv Pruthi, M.B.B.S., explains how Mayo Clinic Laboratories’ serotonin release assay achieves high sensitivity and specificity while avoiding the use of radioactive materials. Serotonin release testing is an important tool in the...
Novel biomarkers added to movement disorders profile - Insights
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.